Monoclonal antibodies generated recombinantly are often used as biochemical markers or as methods for developing effective therapeutic treatments – targeting cancer, autoimmune disorders, and a broad range of other diseases. From codon optimization for antibody sequences to production of desired antibodies, Azenta Life Sciences now offers researchers a range of flexible and tailored recombinant antibody production solutions that save valuable time and help accelerate innovation.
In this video you’ll learn how Azenta can:
• Increase reproducibility, control, and consistency
• Give faster production time over hybridoma technology
• Easier to switch antibodies into a preferable format
• Reduce project risk profile with access to domestic services and support
#Azenta #AzentaLifeSciences #antibody #antibodydiscovery #recombinantantibodyproduction #gene-to-antibody #monoclonalantibodies #antibodyconstruct #antibodyDNAsynthesis #antibodyexpression #antibodypurification #antibodylibrary #antibodychains #antibodysequence
